Konex (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene expression to suppress the production of inflammatory cytokines and chemokines. This reduces leukocyte infiltration and edema, providing anti‑inflammatory and immunosuppressive effects on the skin.

The dosage of Konex is determined by the prescribing healthcare professional based on the severity of the skin condition, the area to be treated and patient-specific factors. Patients should follow the exact instructions provided on the prescription label.

Safety data for mometasone furoate in pregnancy and lactation are limited. Healthcare providers generally weigh the potential benefits against any possible risks before prescribing. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician.

To request Konex, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Konex (mometasone furoate) is a high‑potency corticosteroid, offering stronger anti‑inflammatory activity than low‑potency agents such as hydrocortisone. Compared with other high‑potency steroids like clobetasol, mometasone often provides a favorable balance of efficacy and lower risk of skin atrophy when used as directed.

Konex should be stored at temperatures below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Konex is a topical formulation applied directly to the affected skin area. The prescribed amount is usually a thin layer, gently rubbed in until fully absorbed. Patients should wash their hands before and after application and avoid contact with eyes, mouth or open wounds unless instructed otherwise.

Serious risks include skin atrophy, telangiectasia, secondary infections, and systemic adrenal suppression, especially with prolonged use over large areas or under occlusion. Patients should report any signs of thinning skin, unusual bruising, or systemic symptoms such as fatigue to their healthcare provider promptly.

Konex is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided on infected, broken or ulcerated skin unless directed by a physician, and used with caution in children and immunocompromised patients.